The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

TERVA Chemoresponse -konsortiomme yhdisti monien alojen asiantuntijat #TervaChemoMeet kokouksessa munasarjasyövän h… twitter.com/i/web/status/1…

We're starting with the first lecture #dmcm2019 from @Sampsa_H of @HautaniemiLab on chemoresistance… twitter.com/i/web/status/1…

Online @nature: The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs nature.com/articles/s4158… #ESMO19

Single-Cell RNA-seq data is notoriously noisy. There are dozens of methods for cleaning it, but how do you know whe… twitter.com/i/web/status/1…